# Safety of Xeloda in Solid Tumours

> **NCT02479217** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1268 (actual)

## Conditions studied

- Metastatic Breast Cancer, Colon Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Xeloda

## Key facts

- **NCT ID:** NCT02479217
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 1268 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02479217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02479217, "Safety of Xeloda in Solid Tumours". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02479217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*